5 Things Regeneron's CEO Said as the Biotech Stock Sank

Regeneron (NASDAQ: REGN) CEO Leonard Schleifer was on the hot seat Monday at the Morgan Stanley healthcare conference. And the timing was either terrific or terrible, depending on your perspective. Regeneron stock opened more than 4% below its previous close, and things got worse during intraday trading.

The big drop came after Regeneron and partner Sanofi (NYSE: SNY) announced phase 3 results for Dupixent in treating asthma. While the study found that the drug reduced severe asthma attacks and improved lung function, some of the results raised concerns. Here's what Regeneron's CEO had to say as the biotech's stock sank.

Image source: Getty Images.

Source: Fool.com